The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Office-Based Treatment of Opiate Addiction with a Sublingual-Tablet Formulation of Buprenorphine and Naloxone
Open accessAbstract
BACKGROUND: Office-based treatment of opiate addiction with a sublingual-tablet formulation of buprenorphine and naloxone has been proposed, but its efficacy and safety have not been well studied. METHODS: We conducted a multicenter, randomized, placebo-controlled trial involving 326 opiate-addicted persons who were assigned to office-based treatment with sublingual tablets consisting of buprenorphine (16 mg) in combination with naloxone (4 mg), buprenorphine alone (16 mg), or placebo given daily for four weeks. The primary outcome measures were the percentage of urine samples negative for opiates and the subjects' self-reported craving for opiates. Safety data were obtained on 461 opiate-addicted persons who participated in an open-label study of buprenorphine and naloxone (at daily doses of up to 24 mg and 6 mg, respectively) and another 11 persons who received this combination only during the trial. RESULTS: The double-blind trial was terminated early because buprenorphine and naloxone in combination and buprenorphine alone were found to have greater efficacy than placebo. The proportion of urine samples that were negative for opiates was greater in the combined-treatment and buprenorphine groups (17.8 percent and 20.7 percent, respectively) than in the placebo group (5.8 percent, P<0.001 for both comparisons); the active-treatment groups also reported less opiate craving (P<0.001 for both comparisons with placebo). Rates of adverse events were similar in the active-treatment and placebo groups. During the open-label phase, the percentage of urine samples negative for opiates ranged from 35.2 percent to 67.4 percent. Results from the open-label follow-up study indicated that the combined treatment was safe and well tolerated. CONCLUSIONS: Buprenorphine and naloxone in combination and buprenorphine alone are safe and reduce the use of opiates and the craving for opiates among opiate-addicted persons who receive these medications in an office-based setting.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Treatment of OUD with B/N has been shown to be medically effective (increasing retention in treatment and decreasing use of illicit opioids) and cost-effective.3–8”
From Implementing Group Visits for Opioid Use Disorder: A Case Series (2020) · cites this paper as [5]
In the citing paper
“While participants’ demographic characteristics were similar to those reported in other U.S. and international studies of office-based buprenorphine/naloxone maintenance, our study sample is not necessarily representative of all opioid-dependent patients.13–15”
From Patient Satisfaction with Primary Care Office-Based Buprenorphine/Naloxone Treatment (2007) · cites this paper as [14]
In the citing paper
“In this study, where craving was measured on a 0–100 mm VAS, mean craving more than halved, with a baseline score of 62.4 reducing to 29.8 after 4 weeks of treatment with a sublingual tablet formulation of 16 mg buprenorphine/4 mg naloxone (p < 0.0001, Figure 4 ) [(111) and unpublished data].”
From Craving in Opioid Use Disorder: From Neurobiology to Clinical Practice (2019) · cites this paper as [111]
In the citing paper
“phase III research reports indicate that buprenorphine maintenance is quite safe with equivalent adverse events to methadone and placebo”
From Maintenance Medication for Opiate Addiction: The Foundation of Recovery (2012) · cites this paper as [83]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Diagnostic and Statistical Manual of Mental Disorders
Williams, J. B. W., & First, M. B. (2013) · Oxford University Press eBooks · doi:10.1093/acrefore/9780199975839.013.104 · Cited by 109,845
A method for estimating the probability of adverse drug reactions
Naranjo, C. A., Busto, U., Sellers, E. M., Sandor, P., Ruiz, I., Roberts, E. A., Janecek, E., Domecq, C., & Greenblatt, D. J. (1981) · Clinical Pharmacology and Therapeutics · doi:10.1038/clpt.1981.154 · Cited by 11,914
Martin, W. R., Eades, C. G., Thompson, J. A., Huppler, R. E., & Gilbert, P. E. (1976) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)30536-7 · Cited by 2,992
A Comparison of Levomethadyl Acetate, Buprenorphine, and Methadone for Opioid Dependence
Johnson, R. E., Chutuape, M. A., Strain, E. C., Walsh, S. L., Stitzer, M. L., & Bigelow, G. E. (2000) · New England Journal of Medicine · doi:10.1056/nejm200011023431802 · Cited by 623
A Controlled Trial of Buprenorphine Treatment for Opioid Dependence
Johnson, R. E. (1992) · JAMA · doi:10.1001/jama.1992.03480200058024 · Cited by 567
Kakko, J., Svanborg, K. D., Kreek, M. J., & Heilig, M. (2003) · The Lancet · doi:10.1016/s0140-6736(03)12600-1 · Cited by 466
Buprenorphine maintenance treatment of opiate dependence: a multicenter, randomized clinical trial
Ling, W., Charuvastra, C., Collins, J. F., Batki, S., Brown, L. S., Kintaudi, P., Wesson, D. R., Mcnicholas, L., Tusel, D. J., Malkerneker, U., et al. (1998) · Addiction · doi:10.1046/j.1360-0443.1998.9344753.x · Cited by 402
Self-citationA controlled trial of buprenorphine treatment for opioid dependence
Johnson, R. E. (1992) · JAMA · doi:10.1001/jama.267.20.2750 · Cited by 199
A placebo controlled clinical trial of buprenorphine as a treatment for opioid dependence
Johnson, R. E., Eissenberg, T., Stitzer, M. L., Strain, E. C., Liebson, I. A., & Bigelow, G. E. (1995) · Drug and Alcohol Dependence · doi:10.1016/0376-8716(95)01186-2 · Cited by 183
Buprenorphine: a controlled clinical trial in the treatment of opioid dependence
Pani, P., Maremmani, I., Pirastu, R., Tagliamonte, A., & Gessa, G. L. (2000) · Drug and Alcohol Dependence · doi:10.1016/s0376-8716(99)00140-4 · Cited by 149
Research works printed but not linked: 2
- 2001, Fed Regist, 66, 4075
- Martin WR, 1976, J Pharmacol Exp Ther, 197, 517
Cited by
Sorted by citations
Items 201–300 of 578
Innovations in agonist maintenance treatment of opioid-dependent patients
Haasen, C., & van den Brink, W. (2006) · Current Opinion in Psychiatry · doi:10.1097/01.yco.0000245759.13997.9d · Cited by 35
Non-medical use and abuse of commonly prescribed medications
Riggs, P. (2008) · Current Medical Research and Opinion · doi:10.1185/030079908x273435 · Cited by 34
Prescribing opioids in older people
Huang, A. R., & Mallet, L. (2012) · Maturitas · doi:10.1016/j.maturitas.2012.11.002 · Cited by 36
Pharmacological therapies for management of opium withdrawal
Rahimi‐Movaghar, A., Gholami, J., Amato, L., Hosseini, L. J., Nooraie, R. Y., & Amin‐Esmaeili, M. (2018) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007522.pub2 · Cited by 34
Apelt, S., Scherbaum, N., Gölz, J., Backmund, M., & Soyka, M. (2013) · Pharmacopsychiatry · doi:10.1055/s-0032-1330033 · Cited by 33
Stein, M. D., Herman, D. S., Moitra, E., Hecht, J., Lopez, R., Anderson, B. J., & Brown, R. A. (2014) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2014.11.007 · Cited by 33
“…50-65% retention rates at 6 months, and the great majority of attrition occurring during the first three months of treatment (Cunningham et al., 2008; Finch et al., 2007; Fudala et al., 2003; Lee et al., 2009; Magura et al., 2007; Mintzer et al., 2007; Soeffing et al., 2009; Stein et al., 2005).”
BackgroundParenteral buprenorphine–naloxone abuse is a major cause of fatal buprenorphine-related poisoning
Häkkinen, M., Heikman, P. K., & Ojanperä, I. A. (2013) · Forensic Science International · doi:10.1016/j.forsciint.2013.06.017 · Cited by 33
Dunlop, A. J., Brown, A. L., Oldmeadow, C. J., Harris, A., Gill, A. J., Sadler, C., Ribbons, K., Attia, J., Barker, D., Ghijben, P., et al. (2017) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2017.01.016 · Cited by 32
Initial Strategies for Integrating Buprenorphine into HIV Care Settings in the United States
Sullivan, L. E., Bruce, R. D., Haltiwanger, D., Lucas, G. M., Eldred, L. J., Finkelstein, R., & Fiellin, D. A. (2006) · Clinical Infectious Diseases · doi:10.1086/508183 · Cited by 33
Extended-Release 7-Day Injectable Buprenorphine for Patients With Minimal to Mild Opioid Withdrawal
D’Onofrio, G., Herring, A. A., Perrone, J., Hawk, K. F., Samuels, E. A., Cowan, E. A., Anderson, E. S., McCormack, R. P., Huntley, K., Owens, P. H., et al. (2024) · JAMA Network Open · doi:10.1001/jamanetworkopen.2024.20702 · Cited by 32
Öhlin, L., Hesse, M., Fridell, M., & Tätting, P. (2011) · BMC Psychiatry · doi:10.1186/1471-244x-11-81 · Cited by 32
“The level of retention in this study is equivalent to well functioning residential treatment programmes as described by Bell (1985) [40], and also comparable to levels of retention in high quality substitution programmes in the USA and in Europe [ 35 ,36].”
ResultEnvironmental enrichment as a potential intervention for heroin seeking
Galaj, E., Manuszak, M., & Ranaldi, R. (2016) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2016.04.016 · Cited by 32
Pharmacological treatment of opioid use disorder in pregnancy
Rodriguez, C. E., & Klie, K. A. (2019) · Seminars in Perinatology · doi:10.1053/j.semperi.2019.01.003 · Cited by 32
“Buprenorphine and buprenorphine/naloxone products have been demonstrated to effectively reduce the use of opiates as well as decrease craving for opiates in those with opioid use disorder.(22) In conjunction with pharmacologic treatment, it is recommended that patients be offered comprehensive, integrated psychosocial…”
BackgroundQuaye, A., Potter, K. W., Roth, S., Acampora, G. A., Mao, J., & Zhang, Y. (2020) · Pain Medicine · doi:10.1093/pm/pnaa020 · Cited by 32
Öhlin, L., Fridell, M., & Nyhlén, A. (2015) · BMC Psychiatry · doi:10.1186/s12888-015-0415-z · Cited by 32
“International studies emphasize the importance of high structure for compliance, retention and positive outcome of maintenance programs [9,14-19].”
Kalluri, H. V., Zhang, H., Caritis, S. N., & Venkataramanan, R. (2017) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.13368 · Cited by 31
Langdon, K. J., Scherzer, C. R., Ramsey, S. E., Carey, K. B., Rich, J. D., & Ranney, M. L. (2021) · Journal of Substance Abuse Treatment · doi:10.1016/j.jsat.2021.108538 · Cited by 30
Zhang, J., Song, C., Dai, J., Li, L., Yang, X., & Chen, Z. (2022) · MedComm · doi:10.1002/mco2.148 · Cited by 32
Spotlight on Buprenorphine/Naloxone in the Treatment of Opioid Dependence†
Orman, J. S., & Keating, G. M. (2009) · CNS Drugs · doi:10.2165/11203740-000000000-00000 · Cited by 29
Successful transition to buprenorphine in a patient with methadone-induced torsades de pointes
Esses, J., Rosman, J. Z., Thanh, L., Schweitzer, P., & Hanon, S. (2008) · Journal of Interventional Cardiac Electrophysiology · doi:10.1007/s10840-008-9280-8 · Cited by 30
The Impact of Cocaine Use on Outcomes in HIV-Infected Patients Receiving Buprenorphine/Naloxone
Sullivan, L. E., Botsko, M., Cunningham, C. O., O’Connor, P. G., Hersh, D., Mitty, J. A., Lum, P. J., Schottenfeld, R. S., & Fiellin, D. A. (2011) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0b013e3182097576 · Cited by 30
Ober, A. J., Watkins, K. E., Hunter, S. B., Lamp, K., Lind, M., & Setodji, C. M. (2015) · Implementation Science · doi:10.1186/s13012-015-0256-7 · Cited by 29
“However, despite the potential benefits of providing SUD screening and treatment in primary care and the existence of evidence-based practices (EBP) suitable for delivery in these settings [13-21], uptake of evidencebased SUD treatments in primary care has been slow.”
BackgroundUrine naloxone concentration at different phases of buprenorphine maintenance treatment
Heikman, P. K., Häkkinen, M., Gergov, M., & Ojanperä, I. A. (2013) · Drug Testing and Analysis · doi:10.1002/dta.1464 · Cited by 29
Office-Based Practice and Opioid-Use Disorders
Clark, H. W. (2003) · New England Journal of Medicine · doi:10.1056/nejmp038126 · Cited by 29
Treatment of opioid-dependent adolescents and young adults with buprenorphine
Subramaniam, G., Fishman, M. J., & WOODY, G. E. (2009) · Current Psychiatry Reports · doi:10.1007/s11920-009-0054-5 · Cited by 29
“The use of buprenorphine in offi ce-based settings that developed as a result of these events is safe and effective [ 20 ] and greatly increased access to medication-assisted treatments for opioid-dependent individuals.”
BackgroundHui, D. S. C., Weinstein, Z., Cheng, D. M., Quinn, E. K., Kim, H. W., LaBelle, C. T., & Samet, J. H. (2017) · Journal of Substance Abuse Treatment · doi:10.1016/j.jsat.2017.05.010 · Cited by 28
“(Bart, 2012; Dunn, Sigmon, Strain, Heil, & Higgins, 2011; Fudala et al., 2003; Kakko, Svanborg, Kreek, & Heilig, 2003; Sordo et al., 2017) Successful buprenorphine treatment retention is associated with reduced mortality, improved social function, decreased illicit drug use, and improved quality of…”
BackgroundBuprenorphine-Containing Treatments
Robinson, S. E. (2006) · CNS Drugs · doi:10.2165/00023210-200620090-00001 · Cited by 28
Mark, T. L., Dilonardo, J. D., Vandivort, R., & Miller, K. (2012) · Journal of Substance Abuse Treatment · doi:10.1016/j.jsat.2012.11.004 · Cited by 28
Counseling and Directly Observed Medication for Primary Care Buprenorphine Maintenance
Moore, B. A., Barry, D. T., Sullivan, L. E., O’Connor, P. G., Cutter, C. J., Schottenfeld, R. S., & Fiellin, D. A. (2012) · Journal of Addiction Medicine · doi:10.1097/adm.0b013e3182596492 · Cited by 28
“Of note, the majority of those early studies included drug counseling and directly observed medication consistent with methadone regulations of the time (Kosten et al., 1993; Schottenfeld et al., 1997; O’Connor et al., 1998; Johnson et al., 2000; Fiellin et al., 2002; Fudala et al., 2003).”
BackgroundNon-Medical Prescription Opioid Use and Prescription Opioid Use Disorder: A Review.
Tetrault, J. M., & Butner, J. L. (2015) · PubMed Central · Cited by 27
Amass, L., Pukeleviciene, V., Subata, E., Almeida, A. R., Pieri, M., D'Egidio, P., Staňková, Z., Costa, A., Smyth, B., Sakoman, S., et al. (2012) · Addiction · doi:10.1111/j.1360-0443.2011.03577.x · Cited by 25
“In an indirect induction strategy, patients receive BPN over the first 2 days as a ‘bridge’ to BNX on day 3 [19,20,22].”
MethodThe effects of time and money prices on treatment attendance for methadone maintenance clients
Borisova, N. N., & Goodman, A. (2003) · Journal of Substance Abuse Treatment · doi:10.1016/s0740-5472(03)00157-0 · Cited by 27
A Case Series of Buprenorphine/Naloxone Treatment in a Primary Care Practice
Doolittle, B. R., & Becker, W. C. (2011) · Substance Abuse · doi:10.1080/08897077.2011.599256 · Cited by 26
“[ 4 , 8 – 10 , 12 ] Further, urine testing revealed that 88% were positive for buprenorphine, suggesting that patients were adherent with the regimen.”
BackgroundHersh, D., Little, S., & Gleghorn, A. A. (2011) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2011.587704 · Cited by 26
“Numerous studies support the efficacy of opiate agonist treatment with either methadone or buprenorphine (Fudala et al. 2003; Fiellin et al. 2002; Johnson et al. 2000; O’Conner et al. 1998; Hubbard et al. 1997; Ball & Ross 1991; Ling et al. 1988).”
BackgroundResultBuprenorphine Prescribing: To Expand or Not to Expand
LI, X., Shorter, D. I., & Kosten, T. R. (2016) · Journal of Psychiatric Practice · doi:10.1097/pra.0000000000000154 · Cited by 26
Guerrero, E. G., Garner, B. R., Cook, B. L., & Kong, Y. (2017) · Addictive Behaviors · doi:10.1016/j.addbeh.2017.05.006 · Cited by 26
“…for opioid dependence, and naltrexone for alcohol or opioid dependence—in conjunction with psychosocial interventions (Comer, Walker, & Collins, 2005; Fudala et al., 2003; Ling & Compton, 2005; http://dx.doi.org/10.1016/j.addbeh.2017.05.006 Received 25 February 2017; Received in revised form 13…”
BackgroundResultInfluentialRosenthal, E. S., Brokus, C. J., Sun, J., Carpenter, J. E., Catalanotti, J. S., Eaton, E., Steck, A., Kuo, I. C., Burkholder, G., Akselrod, H., et al. (2023) · AIDS · doi:10.1097/qad.0000000000003629 · Cited by 25
“Medication for opioid use disorder (MOUD) is an evidence-based strategy to treat opioid use disorder (OUD) by reducing craving and withdrawal, opioid use frequency, risk behaviors [6,7], and mortality [8].”
BackgroundUsing buprenorphine to facilitate entry into residential therapeutic community rehabilitation
Collins, E. D., Horton, T. L., Reinke, K., Amass, L., & Nunes, E. V. (2006) · Journal of Substance Abuse Treatment · doi:10.1016/j.jsat.2006.03.018 · Cited by 25
“It has been shown to be an effective medication for ameliorating the symptoms of opioid withdrawal and for the maintenance treatment of opioid dependence (Fudala et al., 2003; Gowing, Ali, & White, 2004; Johnson, Strain, & Amass, 2003).”
BackgroundPatterns of physician prescribing for opioid maintenance treatment in Ontario, Canada in 2014
Guan, Q., Khuu, W., Spithoff, S. M., Kiran, T., Kahan, M., Tadrous, M., Martins, D., Leece, P., & Gomes, T. (2017) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2017.05.002 · Cited by 25
Accurso, A. J., & Rastegar, D. A. (2015) · Journal of Substance Abuse Treatment · doi:10.1016/j.jsat.2015.09.004 · Cited by 24
Buprenorphine tablet versus liquid: A clinical trial comparing plasma levels, efficacy, and symptoms
Chawarski, M. C., Moody, D. E., Pakes, J., O’Connor, P. G., & Schottenfeld, R. S. (2005) · Journal of Substance Abuse Treatment · doi:10.1016/j.jsat.2005.08.011 · Cited by 24
“…and daily doses of 8–16 mg of sublingual (SL) liquid are generally well tolerated and more efficacious than lower doses (Bickel et al., 1988; Fudala et al., 2003; Johnson et al., 2000; Johnson, Jaffe, & Fudala, 1992; Kosten, Schottenfeld, Ziedonis, & Falcioni, 1993; Ling et al., 1998;…”
BackgroundMeredith, L. S., Komaromy, M. S., Cefalu, M. S., Murray-Krezan, C. M., Page, K., Osilla, K. C., Dopp, A. R., Leamon, I. M., Tarhuni, L., Hindmarch, G., et al. (2021) · Contemporary Clinical Trials · doi:10.1016/j.cct.2021.106354 · Cited by 23
Kresina, T. F., Eldred, L. J., Bruce, R. D., & Francis, H. L. (2005) · AIDS · doi:10.1097/01.aids.0000192093.46506.e5 · Cited by 23
“A recent randomized, placebo-controlled clinical trial [32], administering buprenorphine/naloxone combination as a modified DOTregimen for 4 weeks resulted in reduced heroin use compared with placebo.”
MethodAccurso, A. J., Lee, J. D., & McNeely, J. (2017) · Journal of Substance Abuse Treatment · doi:10.1016/j.jsat.2017.10.002 · Cited by 22
Self-Help Groups And Medication Use In Opioid Addiction Treatment: A National Analysis
Wen, H., Druss, B. G., & Saloner, B. K. (2020) · Health Affairs · doi:10.1377/hlthaff.2019.01021 · Cited by 22
Crystal, S., Nowels, M., Samples, H., Olfson, M., Williams, A. R., & Treitler, P. C. (2022) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2022.109269 · Cited by 22
Sociodemographic Differences in Quality of Treatment to Medicaid Enrollees Receiving Buprenorphine
Landis, R. K., Levin, J. S., Saloner, B. K., Gordon, A. J., Dick, A. W., Sherry, T. B., LESLIE, D. L., Sorbero, M., & Stein, B. D. (2022) · Substance Abuse · doi:10.1080/08897077.2022.2060424 · Cited by 23
“[7] Fudala PJ, Bridge TP, Herbert S, et al.”
BackgroundBaxley, C., Borsari, B. E., Reavis, J. V., Manuel, J. K., Herbst, E. D., Becker, W. C., Pennington, D., Batki, S. L., & Seal, K. H. (2022) · Addictive Behaviors · doi:10.1016/j.addbeh.2022.107589 · Cited by 22
Buprenorphine Dose Induction in Non-Opioid-Tolerant Pre-release Prisoners
Vocci, F., Schwartz, R., Wilson, M. E., Gordon, M., Kinlock, T., Fitzgerald, T. T., O'Grady, K., & Jaffe, J. (2015) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2015.09.001 · Cited by 24
“…research participants who had a history of opioid dependence and were either physiologically dependent at the time of the study (Amass et al., 1998; Fudala et al., 2003; Johnson et al., 1989; Ling et al., 1998; Magura et al., 2009) or were actively using (and likely tolerant to some degree) at…”
BackgroundSoens, M., He, J., & Bateman, B. T. (2019) · Seminars in Perinatology · doi:10.1053/j.semperi.2019.01.004 · Cited by 23
Dong, R., Wang, H., Li, D., Lang, L., Gray, F. A., Liu, Y., Laffont, C. M., Young, M. A., Jiang, J., Liu, Z., et al. (2019) · Drugs in R&D · doi:10.1007/s40268-019-0277-9 · Cited by 22
Proctor, S. L., Copeland, A. L., Kopak, A. M., Herschman, P. L., & Polukhina, N. (2014) · Experimental and Clinical Psychopharmacology · doi:10.1037/a0037550 · Cited by 22
Kresina, T. F., Bruce, R. D., Cargill, V. A., & Cheever, L. W. (2005) · Clinical Infectious Diseases · doi:10.1086/429502 · Cited by 22
Unger, A., Martin, P., Kaltenbach, K. A., Stine, S. M., Heil, S. H., Jones, H. E., Arria, A. M., Coyle, M. G., Selby, P. L., & Fischer, G. (2010) · European Addiction Research · doi:10.1159/000284683 · Cited by 21
“American and European pregnant women can equally benefit from maintenance treatment during pregnancy, yet differences in prescribing exist between the USA, Canada and Austria. In the USA, office-based maintenance treatment has only been established since 2002 with the approval of the buprenorphine-naloxone combination…”
BackgroundSelf-citationKumari, S., Manalai, P., Leong, S., Wooditch, A., Malik, M. A., & Lawson, W. B. (2016) · American Journal on Addictions · doi:10.1111/ajad.12325 · Cited by 21
“Many studies show that office-based buprenorphine (BUP) treatment is feasible and effective in reducing illicit opioid use.(10,11) There is significant evidence showing that non-adherence to medications in general is associated with adverse outcomes and increased health care costs.”
BackgroundZhu, Y., Coyle, D. T., Mohamoud, M., Zhou, E. H., Eworuke, E., Dormitzer, C. M., & Staffa, J. A. (2018) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2018.02.019 · Cited by 20
“MAT is a mainstay of treatment for OUD and has been shown to be effective in reducing opioid use and opioid craving among affected individuals (Connery, 2015; Fiellin et al., 2006; Fudala et al., 2003; Volkow et al., 2014).”
BackgroundSamson, K. R., Xu, W., Kortagere, S., & España, R. A. (2022) · Addiction Biology · doi:10.1111/adb.13241 · Cited by 22
Levy, S., Vaughan, B. L., Angulo, M., & Knight, J. R. (2007) · Journal of Adolescent Health · doi:10.1016/j.jadohealth.2006.11.142 · Cited by 20
Doorley, S. L., Ho, C. J., Echeverria, E., Preston, C., Ngo, H., Kamal, A., & Cunningham, C. O. (2016) · Substance Abuse · doi:10.1080/08897077.2016.1264535 · Cited by 21
Treatment of Heroin Dependence: Effectiveness, Costs, and Benefits of Methadone Maintenance
SCHILLING, R. F., Dornig, K., & Lungren, L. (2005) · Research on Social Work Practice · doi:10.1177/1049731505277059 · Cited by 20
“…in fixed combination with naloxone for the treatment of opiate dependence, MM appears to be marginally favorable to these medications with respect to cost and the usual outcome indicators of heroin use and dropout (Fudala et al., 2003; Ling & Wesson, 2003; Mattick, Breen, Kimer, & Davoli, 2003).”
BackgroundSyringe access for the prevention of blood borne infections among injection drug users
Stancliff, S., Agins, B., Rich, J. D., & Burris, S. C. (2003) · BMC Public Health · doi:10.1186/1471-2458-3-37 · Cited by 20
Galarneau, L. R., Scheuermeyer, F. X., Hilburt, J., O'Neill, Z. R., Barbic, S. P., Moe, J., Buxton, J. A., Orkin, A. M., Kaczorowski, J. A., Dong, K. A., et al. (2023) · Annals of Emergency Medicine · doi:10.1016/j.annemergmed.2023.02.007 · Cited by 19
Office-Based Opioid Dependence Treatment
Colson, J. D. (2012) · Pain Physician · doi:10.36076/ppj.2012/15/es231 · Cited by 19
Addressing the Need for Treatment Paradigms for Drug-Abusing Patients with Multiple Morbidities
Kresina, T. F., Normand, J., Khalsa, J. H., Mitty, J. A., Flanigan, T., & Francis, H. L. (2004) · Clinical Infectious Diseases · doi:10.1086/421403 · Cited by 19
“Pharmacotherapy for drug abuse or addiction mainly comprises opioid maintenance treatment, for opiate addiction, as well as the newly approved buprenorphine/naloxone combination [34, 35].”
BackgroundDiscontinuing Buprenorphine Treatment of Opioid Use Disorder: What Do We (Not) Know?
Connery, H. S., & Weiss, R. D. (2020) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2019.19121245 · Cited by 19
McNicholas, L. F., Holbrook, A. M., O’Grady, K. E., Jones, H. E., Coyle, M. G., Martin, P., Heil, S. H., Stine, S. M., & Kaltenbach, K. A. (2012) · Addiction · doi:10.1111/j.1360-0443.2012.04043.x · Cited by 18
Self-citationMedication-Assisted Treatment With Buprenorphine: Assessing the Evidence
Parks, C. L., Fullerton, C. A., Kim, M. L., Montejano, L. B., Lyman, D. R., Dougherty, R. H., Daniels, A. S., Ghose, S. S., & Delphin-Rittmon, M. E. (2015) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/appi.focus.130309 · Cited by 18
Savage, S. A., Abraham, A. J., Knudsen, H. K., Rothrauff, T. C., & Roman, P. M. (2011) · Journal of Substance Abuse Treatment · doi:10.1016/j.jsat.2011.06.009 · Cited by 18
“Although the effectiveness of treating opioid dependence with buprenorphine has been demonstrated in numerous clinical trials (Fudula et al., 2003; Johnson et al., 2000; Johnson, Jaffe, & Fudula, 1992; Ling et al., 2005; Lintzeris, Bell, Bammer, Jolley, & Rushworth, 2002; Pani, Maremmani,…”
BackgroundBuprenorphine-naloxone use in pregnancy for treatment of opioid dependence
Dooley, J., Gerber-Finn, L., Antone, I., Guilfoyle, J., Blakelock, B., Balfour-Boehm, J., Hopman, W. M., Jumah, N. A., & Kelly, L. (2016) · Europe PMC (PubMed Central) · Cited by 21
Models of Resident Physician Training in Opioid Use Disorders
Graddy, R., Accurso, A. J., Nandiwada, D. R., Shalaby, M., & Holt, S. R. (2019) · Current Addiction Reports · doi:10.1007/s40429-019-00271-1 · Cited by 18
Ingestion of High‐Dose Buprenorphine by a 4 Year‐Old Child
Gaulier, J., Charvier, F., Monceaux, F., Marquet, P., & Lachâtre, G. (2004) · Journal of Toxicology Clinical Toxicology · doi:10.1081/clt-200042470 · Cited by 18
“However, when taken sublingually, as prescribed, buprenorphine has a greater bioavailability and the opiod agonist effect used to treat the addiction will prevail (9).”
BackgroundRecent advances in the treatment of opiate addiction
Ling, W. W., & Compton, P. A. (2005) · Clinical Neuroscience Research · doi:10.1016/j.cnr.2005.08.012 · Cited by 18
“[77] Fudala PJ, Bridge TP, Herbert S, et al.”
InfluentialSelf-citationIntegrating Data 2000 Waiver Training into Undergraduate Medical Education: The Time is Now
Riser, E., Holterman, L. A., Maruti, S., Brooklyn, J. R., DeVoe, S. G., Tompkins, B. J., Drouin, J., & Sobel, H. G. (2021) · Substance Abuse · doi:10.1080/08897077.2021.1903653 · Cited by 17
Treatment Outcome for Flexible Dosing Buprenorphine Maintenance Treatment
Fareed, A., Vayalapalli, S., Casarella, J., & Drexler, K. P. G. (2011) · The American Journal of Drug and Alcohol Abuse · doi:10.3109/00952990.2011.643988 · Cited by 17
Minding the brain: the role of pharmacotherapy in substance-use disorder treatment
Dakwar, E., & Kleber, H. D. (2017) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2017.19.3/hkleber · Cited by 17
Schiffer, F., Khan, A., Bolger, E. A., Flynn, E., Seltzer, W. P., & Teicher, M. H. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.713686 · Cited by 17
“Fudala and associates (66) reported a 4-week treatment study of buprenorphine vs.”
BackgroundMartı́nez-Raga, J., Saiz, F. G., Pascual, C., Casado, M. Á., & Torres, F. J. S. (2009) · European Addiction Research · doi:10.1159/000259614 · Cited by 15
“Despite availability, increasingly easy access, popularity, and the well-documented effectiveness of MM programs, many patients fail to improve and are unable to achieve and to maintain abstinence while on methadone. In addition, the regulated environment in which methadone is generally dispensed (often at clinics ser…”
BackgroundDrug Abuse by Adolescents: General Considerations
Sanchez-Samper, X., & Knight, J. R. (2009) · Pediatrics in Review · doi:10.1542/pir.30-3-83 · Cited by 17
Buprenorphine for Chronic Pain Management: a Narrative Review
Vu, P. D., Bansal, V., Chitneni, A., Robinson, C. L., Viswanath, O., Urits, I., Kaye, A. D., Nguyen, A., Govindaraj, R., Chen, G. H., et al. (2023) · Current Pain and Headache Reports · doi:10.1007/s11916-023-01185-4 · Cited by 20
“Concurrently, the formed Cooperative Research and Development Agreement between NIDA and R&C supported three landmark studies by Johnson et al., Ling et al., and Fudala et al., which were all pivotal for FDA approval of buprenorphine for opioid addiction and dependence [16–18].”
Animal models for opioid addiction drug discovery
Grenald, S. A., Largent‐Milnes, T. M., & Vanderah, T. W. (2014) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2014.966076 · Cited by 16
“Abuse liability is chronic and requires long-term treatment [91]; therefore, psychosocial interventions are used in conjunction with pharmacological approaches to reduce psychological dependence [91-97].”
BackgroundHealthcare utilization and costs associated with treatment for opioid dependence
Shah, A. M., Duncan, M. E., Atreja, N., Tai, K., & Gore, M. R. (2018) · Journal of Medical Economics · doi:10.1080/13696998.2018.1427101 · Cited by 17
“Both medications are effective in reducing the use of other opiate drugs; buprenorphine is also associated with reduced cravings for opiates[14, 22].”
BackgroundUrban, V., & Sullivan, R. (2008) · Europe PMC (PubMed Central) · Cited by 16
Brown, R. A., Bloom, E. L., Hecht, J., Moitra, E., Herman, D. S., & Stein, M. D. (2014) · Behavior Modification · doi:10.1177/0145445514538279 · Cited by 16
“…months, and the great majority of attrition occurring during the first 3 months of treatment (Cunningham et al., 2008; Finch, Kamien, & Amass, 2007; Fudala et al., 2003; Lee, Grossman, DiRocco, & Gourevitch, 2009; Magura et al., 2007; Mintzer et al., 2007; Soeffing, Martin, Fingerhood, Jasinski, &…”
BackgroundBuprenorphine dosing choices in specific populations: review of expert opinion
Maremmani, I., Rolland, B., Somaini, L., Roncero, C., Reimer, J., Wright, N. M. J., Littlewood, R., Krajči, P., Alho, H., D’Agnone, O., et al. (2016) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2016.1209486 · Cited by 16
“[8,13,23], may be achieved with buprenorphine doses in the range of 8–24 mg/day; doses of 4 mg or less will not be as effective in retaining patients in treatment or reducing heroin”
BackgroundManaging Pain during Pregnancy and Lactation
Nagpal, G., & Rathmell, J. P. (2013) · Elsevier eBooks · doi:10.1016/b978-0-323-08340-9.00035-9 · Cited by 16
González-Saiz, F., Rojas, Ó. L. L., Trujols, J., Alcaraz, S., Siñol, N., & Cobos, J. P. D. L. (2018) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2017.10.035 · Cited by 15
The medical management of opioid dependence in HIV primary care settings
Lum, P. J., & Tulsky, J. P. (2006) · Current HIV/AIDS Reports · doi:10.1007/s11904-006-0016-z · Cited by 16
“Using urine toxicology and treatment retention outcomes, these studies show that buprenorphine is more efficacious than placebo [67,68], equivalent or better than methadone maintenance [69,70], cost-effective [71], and feasible in Medical Management of Opioid Dependence in HIV Lum and Tulsky 199 office-based settings…”
MethodLandis, R. K., Opper, I., Saloner, B. K., Gordon, A. J., LESLIE, D. L., Sorbero, M., & Stein, B. D. (2022) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2022.109669 · Cited by 15
Donohue, J. M., Barry, C. L., Stuart, E. A., Greenfield, S. F., Song, Z., Chernew, M. E., & Huskamp, H. A. (2017) · Journal of Addiction Medicine · doi:10.1097/adm.0000000000000368 · Cited by 15
Novel Formulations of Buprenorphine for Treatment of Opioid Use Disorder
Rosenthal, R. N. (2019) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/appi.focus.20180043 · Cited by 15
Stock, C. J., & Shum, J. (2004) · Journal of Pain & Palliative Care Pharmacotherapy · doi:10.1080/j354v18n03_04 · Cited by 15
I Heard about it from a Friend: Assessing Interest in Buprenorphine Treatment
Fox, A. D., Shah, P. A., Sohler, N., Lopez, C. M., Starrels, J. L., & Cunningham, C. O. (2013) · Substance Abuse · doi:10.1080/08897077.2013.804484 · Cited by 14
Buprenorphine for acute heroin detoxification: Diffusion of research into practice
Kovas, A. E., McFarland, B. H., McCarty, D. J., Boverman, J. F., & Thayer, J. A. (2006) · Journal of Substance Abuse Treatment · doi:10.1016/j.jsat.2006.08.003 · Cited by 15
“More research also is needed to evaluate office-based buprenorphine treatment, which has the potential to increase access, reduce stigma, and facilitate treatment coordination with other medical conditions (Fudala et al., 2003; NIH Consensus Panel, 1998; Rounsaville & Kosten, 2000; Schnoll, 2001).”
BackgroundSamuels, A., Baum, M. L., Luchsinger, J. R., Mealer, R. G., & Ross, R. (2021) · Cambridge University Press eBooks · doi:10.1017/9780511846403.002 · Cited by 15
Sokol, R., Albanese, M., Chew, A., Early, J., Grossman, E., Roll, D., Sawin, G., Wu, D. J., & Schuman-Olivier, Z. (2019) · Addiction Science & Clinical Practice · doi:10.1186/s13722-019-0176-y · Cited by 14
Fatkin, T., Moore, S. K., Okst, K., Creedon, T. B., Samawi, F., Fredericksen, A. K., Roll, D., Oxnard, A., Lê Cook, B., & Schuman-Olivier, Z. (2021) · Journal of Substance Abuse Treatment · doi:10.1016/j.jsat.2021.108415 · Cited by 14
Treating Opioid Use Disorder and Opioid Withdrawal in the Context of Fentanyl
Martinez, S., Ellis, J. D., Bergeria, C. L., Huhn, A. S., & Dunn, K. E. (2025) · Annual Review of Clinical Psychology · doi:10.1146/annurev-clinpsy-081423-023518 · Cited by 16
“Buprenorphine is classified as a Schedule III medication, which allows it to be prescribed directly from a provider’s office for the treatment of OUD (Fudala et al. 2003).”
Ito, G., & Kanemoto, K. (2013) · Psychogeriatrics · doi:10.1111/psyg.12007 · Cited by 14
Tervonen, H. E., Pentikäinen, H., & Tacke, U. (2013) · Journal of Substance Abuse Treatment · doi:10.1016/j.jsat.2013.01.003 · Cited by 14
“Buprenorphine has enabled the provision of OST in office-based settings as well as in primary health care (Fudala et al., 2003; Lintzeris, Ritter, Panjari, Clark, Kutin, & Bammer, 2004; Auriacombe, Fatseas, Dubernet, Daulouede, & Tignol, 2004; Cozzolino et al., 2006; Fiellin et al., 2008).”
MethodAssoumou, S. A., Paniagua, S. M., Gonzalez, P., Wang, J., Beckwith, C. G., White, L. F., Taylor, J. L., Coogan, K., Samet, J. H., & Linas, B. P. (2021) · AIDS and Behavior · doi:10.1007/s10461-021-03220-0 · Cited by 14
Metadata
- Authors
- Fudala, P. J., Bridge, T. P., Herbert, S., Williford, W. O., Chiang, C. N., Jones, K., Collins, J., Raisch, D., Casadonte, P., Goldsmith, R. J., Ling, W., Malkerneker, U., McNicholas, L., Renner, J., Stine, S., & Tusel, D.
- Affiliations
- Veterans Health Administration (US)
- National Institutes of Health (US)
- University of Maryland, Baltimore (US)
- Perry Point VA Medical Center (US)
- University of New Mexico (US)
- VA NY Harbor Healthcare System (US)
- Cincinnati VA Medical Center (US)
- VA West Los Angeles Medical Center (US)
- Edward Hines, Jr. VA Hospital (US)
- University of Pennsylvania (US)
- Boston University (US)
- VA Connecticut Healthcare System (US)
- San Francisco VA Medical Center (US)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2003-09-04
- Volume
- 349
- Issue
- 10
- Pages
- 949-958
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2147528480
- Cited by
- 577
- References
- 30
- Citations by year
- 2026: 3 · 2025: 11 · 2024: 20 · 2023: 26 · 2022: 22 · 2021: 45 · 2020: 24 · 2019: 20 · 2018: 23 · 2017: 27 · 2016: 24 · 2015: 32 · 2014: 31 · 2013: 36 · 2012: 33
- FWCI
- 24.36
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute on Drug Abuse (3Y01-DA-30011-04)
- Topics
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Opioid Use Disorder Treatment
- Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
- Health Sciences › Medicine › Anesthesiology and Pain Medicine › Pain Management and Opioid Use
- Keywords
- opioid use disorder, buprenorphine, naloxone, sublingual tablets, office-based treatment, opioid craving, urine drug testing, drug safety, opioid use reduction
- MeSH terms
- Administration, Sublingual, Adult, Ambulatory Care, Buprenorphine, Double-Blind Method, Drug Therapy, Combination, Female, Humans, Male, Middle Aged, Naloxone, Narcotic Antagonists, Opioid-Related Disorders, Narcotics, Office Visits, Treatment Outcome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
